Loading organizations...
§ Private Profile · Branford, CT, USA
Tangen Biosciences is a technology company.
Tangen Biosciences develops medical instruments for rapid nucleic acid detection, focusing on advanced molecular diagnostics. Its core offering, the TangenDx platform, provides quick and accurate pathogen identification. This technology aims to deliver swift diagnostic results, which is crucial for timely medical interventions in healthcare settings.
Founded in 2013 by John Davidson, Tangen Biosciences emerged from the insight that a critical need existed for accelerated and precise diagnostic tools. Davidson's vision centered on developing innovative DNA detection methods to address limitations in existing diagnostic approaches. The company is currently led by CEO Richard C. Birkmeyer, PhD, an executive with prior experience in the diagnostics field.
The company's diagnostic products serve clinical laboratories and healthcare providers who require expedited pathogen identification. Tangen Biosciences envisions transforming the landscape of infectious disease diagnosis by enabling faster clinical decision-making. Its long-term goal involves expanding the application of its rapid molecular diagnostic platform to improve patient outcomes across various medical conditions.
Tangen Biosciences has raised $21.2M across 2 funding rounds.
Tangen Biosciences has raised $21.2M in total across 2 funding rounds.
Tangen Biosciences has raised $21.2M across 2 funding rounds. Most recently, it raised $12.2M Series B in August 2020.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Aug 6, 2020 | $12.2M Series B | — | Connecticut Innovations, Leading Edge Ventures, Parvizi Surgical, VC23 | Announced |
| Jun 1, 2019 | $9M Series A | Connecticut Innovations | Sway Ventures | Announced |
Tangen Biosciences has raised $21.2M in total across 2 funding rounds.
Tangen Biosciences's investors include Connecticut Innovations, Leading Edge Ventures, Parvizi Surgical, VC23, Sway Ventures.
Tangen Biosciences is a molecular diagnostics company founded in 2013 in Branford, Connecticut, developing the TangenDx™ platform—a portable, low-cost system for rapid nucleic acid detection from diverse samples like whole blood, sputum, or swabs[1][2][3][4][5]. It serves healthcare providers, clinics, pharmacies, rural areas, and potentially bioterrorism response by solving the need for fast, sensitive, lab-independent testing for infections like sepsis, COVID-19, antibiotic resistance, and anthrax, targeting the $3B bloodstream infection market with superior speed (under 1 hour), multi-target capability (up to 33 targets per sample), and simplicity over PCR or culture methods[1][2][3][4]. Growth includes BARDA funding for COVID-19 tests, USG contracts for anthrax detection, and planned launches like a FluA/B, RSV, SARS-CoV-2 panel, with ongoing assay development for sepsis and fungal panels[1][3][4].
Tangen Biosciences emerged from the vision of co-founder John Davidson, PhD, Chief Science Officer with a Harvard biochemistry PhD and 14 years in DNA technologies, including senior roles at Ion Torrent/Life Technologies where he commercialized sequencing platforms[2]. The idea addressed molecular diagnostics' failure to disrupt blood culture for bloodstream infections (BSI) due to poor sensitivity, despite speed advantages; Tangen's team—experienced in revolutionary molecular tools—developed core IP-pending technologies like the LVC™ sample processor, RAMP amplification disk, and GeneSpark™ instrument to enable extreme sensitivity from any sample volume[1][2]. Early traction featured a planned 2019 US launch post-$8M Series A and 510(k) clearance for sepsis, plus contracts like USG anthrax testing, evolving from lab-bound tech to portable solutions amid COVID-19 opportunities[1][2][3].
Tangen rides the point-of-care (POC) diagnostics trend, decentralizing molecular testing from labs to enable rapid pathogen ID amid rising antimicrobial resistance, pandemics, and global health inequities—timing amplified by COVID-19 accelerating BARDA-funded POC needs[1][3][4]. Market forces like the $3B BSI/sepsis diagnostics gap (where molecular tech lagged culture methods) favor its breakthrough sensitivity from unprocessed blood, positioning it against PCR limitations in non-lab settings[2]. It influences the ecosystem by enabling rural/global access, bioterrorism preparedness (e.g., anthrax contracts), and faster antibiotic guidance, potentially transforming outcomes in infectious disease management[1][2].
Tangen's portable, multi-target platform positions it for expansion into sepsis commercialization, new assays (e.g., antibiotic sensitivity from blood in <1 hour), and broader POC adoption as AI-enhanced diagnostics and resistance tracking grow[1][2]. Regulatory wins like 510(k) and more BARDA/USG deals could drive partnerships with pharma or health systems, evolving its influence from niche innovator to sepsis/POCD leader. With momentum from COVID-era validations, expect scaled global impact, circling back to its core promise: high-quality molecular testing anywhere, anytime[3][4].